SOLUBLE FORMS OF TYPES 1 AND 2 ENDOTHEL GROWTH FACTOR RECEPTORS IN BLOOD SERUM OF RENAL-CELL CANCER PATIENTS

DOI: https://doi.org/10.29296/25877313-2018-01-08
Download full text PDF
Issue: 
1
Year: 
2018

A.V. Kolpakov Applicant, A.I. Evdokimov Moscow State University of Medicine Dentistry (Moscow) E.S. Gershnein Dr.Sc. (Biol.), Professor, Leading Research Scientist, N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russia (Moscow) E-mail: esgershtein@gmail.com I.V. Babkina Dr.Sc. (Med.), Leading Research Scientist, N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russia (Moscow) S.D. Bezanova Post-graduate Student, N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russia (Moscow) A.A. Morozov Applicant, A.I. Evdokimov Moscow State University of Medicine Dentistry (Moscow) A.A. Alferov Post-graduate Student, A.I. Evdokimov Moscow State University of Medicine Dentistry (Moscow) N.A. Ognerubov Dr.Sc. (Med.), Professor, Tambov State University named after G.R. Derzhavin (Tambov) D.Yu. Pushkar Dr.Sc. (Med.), Professor, Member-Corr. RAS, Head of the Department of Urology, A.I. Evdokimov Moscow State University of Medicine Dentistry

The data of the comparative enzyme immunoassay VEGFR1 and VEGFR2 in the blood serum of 24 healthy donors, 100 untreat-ed patients with renal cell carcinoma and 14 patients with benign neoplasm of the kidney aged from 29 to 84 years are presented. VEGFR1 and VEGFR2 concentrations were determined in blood serum by R&D ELISA kits (USA). To process the results obtained, we used the statistical software package «Statistica for Windows» and SPSS. Significantly higher median VEGFR1 concentration was de-tected in blood serum of renal cell carcinoma patients as compared to the control (105 and 83 pg/ml, respectively, p = 0.03), but it did not differ from that in patients with benign kidney neoplasms (94 pg/ml). Median VEGFR2 concentration was also significantly higher in patients with kidney cancer than in the control group (13.4 and 9.7 ng/ml, respectively, p = 0.013) and did not differ from the marker level in patients with benign neoplasm of the kidney (13.3 ng/ml). Medians of VEGFR1 content in patients with stage I-II kidney cancer did not differ significantly (101 and 110 pg/ml, respectively), but were significantly lower than in patients with stage III-IV disease (123 pg/ml and 131 pg/ml respectively, p = 0.018). No significant differences in the levels of VEGFR2 at different stages of renal cell carcinoma were found. VEGFR1 and VEGFR2 levels were not related to patients’ age and sex degree of tumor differentiation and its morphological structure. In patients with T3 kidney cancer, VEGFR1 levels were significantly higher than in those with T1. Me-dian VEGFR2 concentration decreased insignificantly with the increase of T criterion and was the lowest in the group of patients with the T4 criterion. VEGFR1 concentration was significantly increased in patients with lymph node involvement corresponding to N2 crite-rion as compared to those with intact lymph nodes (medians 143 pg/ml and 104 pg/ml, respectively). No differences in VEGFR1 and VEGFR2 serum levels in patients with renal cell carcinoma depending on the presence or absence of distant metastases were found. The results obtained testify to the prospects of further studies of VEGFR1 and VEGFR2 content in peripheral blood of patients with kid-ney cancer in order to reveal the possibility of their application in monitoring and evaluating the disease prognosis.

Keywords: 
kidney cancer
VEGFR1
VEGFR2
blood serum

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bezhanova S.D. Opuholi pochek. Novaja klassifikatsija opuholej urogenital'noj sistemy Vsemirnoj organizatsii zdravoohranenija 2016 g. // Arhiv patologii. 2017.
  2. T. 79. № 2. S. 48-52 (Bezhanova S.D. Opukholi pochek. Novaya klassifikatsiya opukholey urogenital’noy sistemy Vsemirnoy organizatsii zdravookhraneniya 2016 g. Arkhiv patologii. 2017; 79(2): 48−52).
  3. Znaor A., Lortet-Tieulent J., Laversanne M., Jemal A., Bray F. International variations and trends in renal cell carcinoma incidence and mortality // Eur. Urol. 2015. V. 67. № 3. R. 519-530.
  4. Siegel R.L., Miller K.D., Jemal A. Cancer statistics // CA Cancer J. Clin. 2016. V. 66. № 1. R. 7-30.
  5. Kaprin A.D., Starinskij V.V., Petrova G.V. (Pod red.) Zlokachestvennye novoobrazovanija v Rossii v 2015 godu (zabolevaemost' i smertnost'). M.: Moskovskij nauchno- issledovatel'skij onkologicheskij institut im. P.A. Gertsena – filial FGBU «Natsional'nyj meditsinskij
  6. issledovatel'skij radiologicheskij tsentr» Minzdrava Rossii. 2017. 250 s. (Kaprin A.D., Starinskiy V.V., Petrova G.V. (Pod red.) Zlokachestvennyye novoobrazovaniya v Rossii v 2015 godu (zabolevayemost’ i smertnost’). M .: Moskovskiy nauchno-issledovatel’skiy onkologicheskiy institut im. P.A. Gertsena - filial FGBU «Natsional’nyy meditsinskiy issledovatel’skiy radiologicheskiy tsentr» Minzdrava Rossii. 2017. 250 s.).
  7. Patel N.S., Muneer A., Blick C., Arya M., Harris A.L. Targeting vascular endothelial growth factor in renal cell carcinoma // Tumour Biol. 2009. V. 30. № 5−6. R. 292 -299.
  8. Davydov M.I., Matveev V.B., Volkova M.I., Begaliev A.K., Feoktistov P.I., Kuznetsov K.P., Nehaev I.V., Lomidze S.V., Zhizhginova O.V., Ogorodnikova E.V., Abgarjan M.G., Chernjaev V.A., Klimov A.V. Hirurgicheskoe lechenie bol'nyh rakom pochki s massivnoj opuholevoj invaziej nizhnej poloj veny // Onkourologija. 2017. V. 13. № 1. R.27 -36 (Davydov M.I., Matveyev V.B., Volkova M.I., Begaliyev
  9. A.K., Feoktistov P.I., Kuznetsov K.P., Nekhayev I.V., Lomidze S.V., Zhizhginova O.V., Ogorodnikova Ye.V.,
  10. Abgaryan M.G., Chernyayev V.A., Klimov A.V. Khirurgicheskoye lecheniye bol’nykh rakom pochki s massivnoy opukholevoy invaziyey nizhney poloy veny. Onkourologiya. 2017; 13 (1): 27−36).
  11. Gershtejn E.S., Kushlinskij D.N. Faktory rosta endotelija sosudov pri razlichnyh onkologicheskih zabolevanijah / V kn.: «Biologicheskie markery opuholej: fundamental'nye i klinicheskie issledovanija» / Pod red.Kushlinskogo N.E. i M.A. Krasil'nikova. M. Izdatel'stvo RAMN. 2017. S. 231 -268 (Gershteyn Ye.S.,Kushlinskiy D.N. Faktory rosta endoteliya sosudov pri razlichnykh onkologicheskikh zabolevaniyakh. V kn .: «Biologicheskiye markery opukholey: fundamental’nyye i klinicheskiye
  12. issledovaniya» / Pod red. Kushlinskogo N.Ye. Krasil’nikova. M. Izdatel’stvo RAMN. 2017; 231−268).
  13. Gospodarowicz D., Abraham J.A., Schillng J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells // Proc. Natl. Sci. USA. 1989. V. 86. № 19. R. 7311 -7315.
  14. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF // Science. 1989. V. 246. № 4935. R. 1309 -1312.
  15. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen // Science. 1989. V. 246. № 4935. R. 1306 -1309.
  16. Conn G., Soderman D.D., Schaeffer M.T., Wile M., Hatcher V.B., Thomas K.A. Purification of a glicoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line // Proc. Natl. Acad. Sci. USA. 1990. V. 87. № 4. R. 1323 -1327.
  17. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis // J. Clin. Oncol. 2005. V. 23. № 5. R. 1011 -1027.
  18. Roskoski R. (Jr.). Vascular endothelial growth factor (VEGF) signaling in tumor progression // Crit. Rev. Oncol. Hematol. 2007. V. 62. № 3. R.179 -213.
  19. Ourradi K., Blythe T., Jarrett C., Barratt S.L., Welsh G.I., Millar A.B. VEGF isoforms have differential effects on permeability of human pulmonary microvascular endothelial cells // Respir. Res. 2017. V. 18. № 1. R. 116.
  20. Gavalas N.G., Liontos M., Trachana S.P., Bagratuni T., Arapinis C., Liacos C., Dimopoulos M.A., Bamias A. Angiogenesisrelated pathways in the pathogenesis of ovarian cancer // Int. J. Mol. Sci. 2013. V. 14. № 8. R. 15885 -15909. Sidibé A., Polena H., Pernet-Gallay K., Razanajatovo J., Mannic T., Chaumontel N., Bama S., Maréchal I., Huber P., Gulino-Debrac D., Bouillet L., Vilgrain I. VE-cadherin Y685F knock-in mouse is sensitive to vascular permeability in recurrent angiogenic organs // Am. J. Physiol. Heart. Circ Physiol. 2014. V. 307. № 3. R. 455 -463.
  21. Scherbakov A.M., Gershtejn E.S., Anurova O.A., Kushlinskij N.E. Faktor rosta endotelija sosudov i ego retseptory pervogo i vtorogo tipa pri rake molochnoj zhelezy // Voprosy onkologii. 2005. T. 51. № 3. S. 317 -321
  22. (Shcherbakov A.M., Gershteyn Ye.S., Anurova O.A., KushlinskiyN.Ye. Faktor rosta endoteliya sosudov i yego
  23. retseptov pervogo i vtorogo tipa pri rake molochnoy zhelezy.Voprosy onkologii. 2005; 51(3): 317−321).
  24. Kim E.A., Gershtejn E.S., Vysotskaja I.V., Kushlinskij N.E. Ekspressija VEGF i VEGFR2 v opuholjah v protsesse neoad'juvantnogo lechenija bol'nyh rakom molochnoj zhelezy// Bjulleten' eksperimental'noj biologicheskoj meditsiny. 2008. T. 145. № 2. S. 206 -209 (Kim Ye.A., Gershteyn Ye.S., Vysotskaya I.V., Kushlinskiy N.Ye. Ekspressiya VEGF i VEGFR2 v opukholyakh v protsesse neoad”yuvannogo lecheniya bol’nykh rakom molochnoy zhelezy. Byull. Eksper. Biol. Med. 2008; 145(2):206−209).
  25. Kushlinskij N.E., Trapeznikova M.F., Gershtejn E.S., Glybin P.V., Kazantseva I.A., Kychakov A.A., Morozov A.P. Faktor rosta endotelija sosudov i ego retseptor 2-go tip pri rake pochki // Voprosy biologicheskoj, meditsinskoj i farmatsevticheskoj himii. 2008. T. 6. № 5. S. 31 -33 (Kushlinskiy N.Ye., Trapeznikova M.F., Gershteyn Ye.S., Glybin P.V., Kazantseva I.A., Kychakov A.A., Morozov A.P. Faktor rosta endoteliya sosudov i yego retseptor 2 tipa pri rake pochki. Voprosy biologicheskoy, meditsinskoy i farmatsevticheskoy khimii. 2008; 6(5):31−33).
  26. Gershtejn E.S., Gritsaenko E.V., Tereshkina I.V., Ognerubov N.A., Kushlinskij N.E. Faktor rosta endotelija sosudov i komponenty sistemy aktivatsii plazminogena vopuholjah bol'nyh rakom endometrija: kliniko-morfologicheskie korreljatsii // Molekuljarnaja meditsina. 2013.№ 6. S. 27 -32 (Gershteyn Ye.S., Gritsayenko Ye.V.,Tereshkina I.V., Ognerubov N.A., Kushlinskiy N.Ye. Faktorrosta endoteliya sosudov i komponentov sistemy aktivatsii plazminogena v opukholyakh bol’nykh rakom endometriya:
  27. kliniko-morfologicheskiye korrelyatsii. Molekulyarnaya meditsina. 2013; 6: 27−32).
  28. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma // J. Clin. Oncol. 2005. V. 23. № 5. R. 1028 -1043.
  29. Folkman J. Tumor angiogenesis // Adv. Cancer Res. 1985. V. 43. R. 175 -230.
  30. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2015. V. 136. № 5. R. 359 -386.
  31. Powles T., Staehler M., Ljungberg B., Bensalah K., Canfield S.E., Dabestani S., Giles R., Hofmann F., Hora M., Kuczyk M.A., Lam T., Marconi L., Merseburger A.S., Volpe A., Bex A. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy // Eur. Urol. 2016. V. 69. № 1. R. 4−6.
  32. Sato K., Tsuchiya N., Sasaki R., Shimoda N., Satoh S., Ogawa O., Kato T. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma // Jpn. J. Cancer Res. 1999. V. 90. № 8. R. 874−879.
  33. Schips L., Dalpiaz O., Lipsky K., Langner C., Rehak P., Puerstner P., Pummer K., Zigeuner R. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group // Eur. Urol. 2007. V. 51. № 1. R. 168−173.
  34. Mihajlenko D.S., Kolpakov A.V., Kushlinskij N.E. Somaticheskie mutatsii – osnovnye sobytija kantserogeneza prisvetlokletochnom rake pochki // Molekuljarnaja meditsina. 2016. T. 14. № 4. S. 3−9 (Mikhaylenko D.S., Kolpakov A.V., Kushlinskiy N.Ye. Somaticheskiye mutatsii − osnovnyye
  35. sobytiya kantserogeneza pri svetloletochnom rake pochki. Molekulyarnaya meditsina. 2016; 14(4):3−9).
  36. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., Eigl B.J., Ruether J.D., Cheng T., North S., Venner P., Knox J.J., Chi K.N., Kollmannsberger C., McDermott D.F., Oh W.K., Atkins M.B., Bukowski R.M., Rini B.I., Choueiri T.K. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study // J. Clin. Oncol. 2009. V. 27. № 34. R. 5794−5799.
  37. Fujita N., Okegawa T., Terado Y., Tambo M., Higashihara E., Nutahara K. Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma // BMC Res. Notes. 2014. № 7. R. 369.
  38. Alekseev B.Ja., Kalpinskij A.S., Muhomed'jarova A.A., Njushko K.M., Kaprin A.D. Targetnaja terapija bol'nyh metastaticheskim rakom pochki neblagoprijatnogo prognoza // Onkourologija. 2017. V. 13. № 2. R. 49−55 (Alekseyev B.Ya., Kalpinskiy A.S., Mukhomed’yarova A.A., Nyushko K.M., Kaprin A.D. Pochvobezopasnosti. Onkourologiya. 2017; 13(2):49−55).
  39. Popov A.M. Targetnaja terapija rasprostranennogo pochechno- kletochnogo raka // Onkourologija. 2017. V. 13. № 2. R. 56−62 (Popov A.M. Targetnaya terapiya rasprostranennogo pochechnokletochnogo raka. Onkourologiya. 2017; 13(2):56−62).
  40. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., Hewitt S.M., Berman A., Steinberg S.M., Liewehr D.J., Plehn J., Doshi A., Thomasson D., McCarthy N., Koeppen H., Sherman M., Zujewski J., Camphausen K., Chen H., Swain S.M. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer // J. Clin. Oncol. 2006. V. 24. № 5. R. 769−777.
  41. Pulaski H.L., Spahlinger G., Silva I.A., McLean K., Kueck A.S., Reynolds R.K., Coukos G., Conejo-Garcia J.R., Buckanovich R.J. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer // J. Transl. Med. 2009. № 7. R. 49 (Published online 2009, June 19).
  42. Sia D., Alsinet C., Newell P., Villanueva A. VEGF signaling in cancer treatment // Curr. Pharm. Des. 2014. V. 20. № 17. R. 2834−2842.